Pfizer Inc (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Symbol
PFE
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$162.14B
52 week range
23.62 - 29.21

Valuation

Share price
$28.12 (close of 2026-10-01)
P/E (TTM)
36.95x
Price to book
1.90x
Price to free cash flow
14.76x
Enterprise value
$224.35B
Book value per share
$15.00

Price performance

PeriodChange
1 day-1.40%
5 days-1.02%
1 month-1.51%
3 months+17.76%
6 months-1.51%
Year to date+12.93%
1 year+3.34%
3 years-15.22%
5 years-34.50%
10 years-12.48%
All time+3329.27%

Members of Congress who disclosed PFE trades

Gilbert Ray Cisneros · Robert Bresnahan · Bruce Westerman · Carol Miller · Jefferson Shreve · Julie Johnson · Lisa McClain · Tommy Tuberville · Alan Armstrong · French Hill · John Boozman · Josh Gottheimer

And 3 others

Super investors holding PFE

Harry Burn (Sound Shore Management) · Prem Watsa (Fairfax Financial Holdings) · Kahn Brothers (Kahn Brothers Group) · Bruce Berkowitz (Fairholme Capital) · Hillman Capital (Hillman Capital Management, Inc)

Profitability and growth

Return on equity
8.96%
Return on assets
3.73%
Gross margin
74.33%
Net margin
12.42%
EBITDA margin
26.79%
Revenue growth
-1.65%
Net income growth
-3.24%
Free cash flow growth
-7.73%

Cash flow and balance sheet

Free cash flow yield (TTM)
6.78%
Current ratio
1.27x
Net debt to EBITDA
4.61x

Latest reported year

Period end
2025-12-31
Fiscal year
2025
Revenue
$62.58B
Cost of revenue
$16.07B
Gross profit
$46.51B
EBITDA
$16.77B
Net income
$7.77B
Earnings per share
$1.37
Interest expense
$2.67B
Shares outstanding
5.68B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$62.58B$46.51B$7.77B$1.37
2024-12-31$63.63B$45.78B$8.03B$1.42
2023-12-31$50.91B$25.96B$2.12B$0.38
2022-12-31$91.79B$57.45B$31.37B$5.59
2021-12-31$73.64B$42.81B$21.98B$3.92
2020-12-31$41.65B$33.17B$9.16B$1.65
2019-12-31$40.91B$32.85B$16.03B$2.88
2018-12-31$40.83B$31.84B$11.15B$1.90
2017-12-31$52.55B$41.32B$21.31B$3.57
2016-12-31$52.82B$40.50B$7.21B$1.18

Margins and returns by year

Period endGross marginNet marginReturn on equity
2025-12-3174.33%12.42%8.96%
2024-12-3171.94%12.62%9.07%
2023-12-3150.99%4.16%2.37%
2022-12-3162.59%34.18%32.71%
2021-12-3158.14%29.85%28.37%
2020-12-3179.63%21.99%14.43%
2019-12-3180.31%39.18%25.26%
2018-12-3177.99%27.32%17.49%
2017-12-3178.63%40.55%29.74%
2016-12-3176.67%13.66%12.06%

Cash and debt by year

Period endCashDebt
2025-12-31$1.14B$61.64B
2024-12-31$1.04B$57.41B
2023-12-31$2.85B$61.54B
2022-12-31$416.00M$32.88B
2021-12-31$1.94B$36.20B
2020-12-31$1.79B$37.13B
2019-12-31$9.65B$35.95B
2018-12-31$18.83B$32.91B
2017-12-31$19.99B$33.54B
2016-12-31$17.85B$31.40B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$9.07B$799.00M
2024-12-31$9.84B$877.00M
2023-12-31$4.79B$525.00M
2022-12-31$26.03B$872.00M
2021-12-31$29.87B$1.18B
2020-12-31$12.18B$755.00M
2019-12-31$10.54B$687.00M
2018-12-31$13.84B$923.00M
2017-12-31$14.85B$840.00M
2016-12-31$14.37B$691.00M

Dividend history

Most recent payment
2026-07-24
Paid in the last twelve months
$1.72
Payment dateDividend per share
2026-07-24$0.43
2026-05-08$0.43
2026-01-23$0.43
2025-11-07$0.43
2025-07-25$0.43
2025-05-09$0.43
2025-01-24$0.43
2024-11-08$0.42

Investor relations

Next earnings report

Next confirmed report
2026-11-03
Consensus EPS estimate
$0.77

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-04Jun/2026$0.68
2026-05-05--
2026-02-03--
2025-11-04--
2025-08-05--
2025-04-29--
2025-02-04--
2024-10-29--

Filings and sources

Company website
pfizer.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Bristol Myers Squibb Co (BMY) · Gilead Sciences, Inc. (GILD) · Biogen Inc. (BIIB) · Amgen Inc (AMGN) · Organon & Co. (OGN) · AstraZeneca plc (AZN) · GSK plc (GSK) · Novartis AG (NVS)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades